跳至主要内容
临床试验/CTRI/2026/04/108053
CTRI/2026/04/108053尚未招募2 期

EVALUATING THE EFFICACY AND SAFETY OF S1 – OXALIPLATIN IN PATIENTS OF UNRESECTABLE AND METASTATIC BILIARY TRACT MALIGNANCIES WITH HYPERBILIRUBINEMIA - A PHASE II TRIAL

PGIMER Chandigarh1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2026年4月16日最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
29
试验地点
1

研究概览

简要总结

In patients that continue to have hyperbilirubinemia post biliary drainage, most of these patients are sent on palliation. in this group, administration of S1 - Oxaliplatin may prolong progression free survival and enhance disease control rate

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 75.00 Year(s)(—)
性别
All

入选标准

  • 18 -75 years, hyperbilirubinemia post biliary draiange (3.75) in histologically/cytologically confirmed biliary tract malignancy.

排除标准

  • ECOG PS greater than or equal to 3, severe uncontrolled neuropathy, knowns cns disease, prior chemotherapy.

研究者

申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Koneti Harshith Sai

PGIMER, Chandigarh

研究点 (1)

Loading locations...

相似试验